JP2008518953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518953A5 JP2008518953A5 JP2007539289A JP2007539289A JP2008518953A5 JP 2008518953 A5 JP2008518953 A5 JP 2008518953A5 JP 2007539289 A JP2007539289 A JP 2007539289A JP 2007539289 A JP2007539289 A JP 2007539289A JP 2008518953 A5 JP2008518953 A5 JP 2008518953A5
- Authority
- JP
- Japan
- Prior art keywords
- polysaccharide
- composition
- composition according
- type
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000004676 glycans Chemical class 0.000 claims 40
- 229920001282 polysaccharide Polymers 0.000 claims 40
- 239000005017 polysaccharide Substances 0.000 claims 40
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims 11
- 230000000890 antigenic effect Effects 0.000 claims 9
- 150000004043 trisaccharides Chemical group 0.000 claims 8
- 241000288906 Primates Species 0.000 claims 7
- 210000002966 serum Anatomy 0.000 claims 7
- 125000005629 sialic acid group Chemical group 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 230000001939 inductive effect Effects 0.000 claims 3
- 238000011081 inoculation Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- 231100000699 Bacterial toxin Toxicity 0.000 claims 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 1
- 102000005348 Neuraminidase Human genes 0.000 claims 1
- 108010006232 Neuraminidase Proteins 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- 239000000688 bacterial toxin Substances 0.000 claims 1
- 230000006196 deacetylation Effects 0.000 claims 1
- 238000003381 deacetylation reaction Methods 0.000 claims 1
- 230000009615 deamination Effects 0.000 claims 1
- 238000006481 deamination reaction Methods 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- 229960003983 diphtheria toxoid Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 229960000814 tetanus toxoid Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62390704P | 2004-11-01 | 2004-11-01 | |
| PCT/US2005/039424 WO2006050341A2 (en) | 2004-11-01 | 2005-11-01 | Modified streptococcal polysaccharides and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008518953A JP2008518953A (ja) | 2008-06-05 |
| JP2008518953A5 true JP2008518953A5 (enExample) | 2008-12-25 |
Family
ID=36319754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007539289A Pending JP2008518953A (ja) | 2004-11-01 | 2005-11-01 | 連鎖球菌修飾多糖類およびそれらの使用法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7858101B2 (enExample) |
| EP (1) | EP1812057A4 (enExample) |
| JP (1) | JP2008518953A (enExample) |
| CN (1) | CN101107010A (enExample) |
| AU (1) | AU2005302269B2 (enExample) |
| CA (1) | CA2586058A1 (enExample) |
| MX (1) | MX2007005202A (enExample) |
| WO (1) | WO2006050341A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0502095D0 (en) * | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
| TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
| GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
| GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
| US9149541B2 (en) | 2011-07-08 | 2015-10-06 | Novartis Ag | Tyrosine ligation process |
| GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
| JP6170932B2 (ja) | 2011-11-07 | 2017-07-26 | ノバルティス アーゲー | ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子 |
| SG11201500978TA (en) | 2012-10-03 | 2015-07-30 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
| GB201300707D0 (en) * | 2013-01-15 | 2013-02-27 | Novartis Ag | Compounds and processes |
| CN105593238B (zh) | 2013-07-11 | 2020-09-08 | 诺华股份有限公司 | 使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰 |
| US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| EP3638301A1 (en) | 2017-06-16 | 2020-04-22 | GlaxoSmithKline Biologicals S.A. | Method of treatment |
| BR112021022429A2 (pt) | 2019-05-10 | 2022-03-22 | Glaxosmithkline Biologicals Sa | Produção de conjugados |
| JP2023503086A (ja) | 2019-11-22 | 2023-01-26 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 細菌サッカリド複合糖質ワクチンの用法及び用量 |
| WO2021250626A2 (en) | 2020-06-12 | 2021-12-16 | Glaxosmithkline Biologicals Sa | Dock tag system |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4207414A (en) | 1978-08-16 | 1980-06-10 | President And Fellows Of Harvard College | Polysaccharide antigens |
| US4324887A (en) | 1978-08-16 | 1982-04-13 | President And Fellows Of Harvard College | Type II group B Streptococci polysaccharide |
| US4438261A (en) | 1980-05-19 | 1984-03-20 | Riker Laboratories, Inc. | Anticoagulant substance |
| US4367222A (en) | 1980-06-09 | 1983-01-04 | President And Fellows Of Harvard College | Immune globulin specific to Group B streptococci |
| US4367221A (en) | 1980-06-09 | 1983-01-04 | President And Fellows Of Harvard College | Immunization against Group B streptococci |
| US4356263A (en) | 1980-06-09 | 1982-10-26 | President And Fellows Of Harvard College | Method of making a polysaccharide vaccine |
| US4367223A (en) | 1980-06-09 | 1983-01-04 | President And Fellows Of Harvard College | Vaccine against Group B streptococci |
| US4284537A (en) | 1980-07-03 | 1981-08-18 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate of streptococcal M protein peptide vaccine |
| US4425330A (en) | 1981-05-20 | 1984-01-10 | Cornell Research Foundation, Inc. | Bovine mastitis vaccine and method for detecting efficacy thereof |
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
| US4619828A (en) | 1982-07-06 | 1986-10-28 | Connaught Laboratories, Inc. | Polysaccharide exotoxoid conjugate vaccines |
| US4757134A (en) | 1982-12-02 | 1988-07-12 | The Rockefeller University | IgA binding protein |
| FR2581877B1 (fr) | 1985-05-14 | 1987-12-18 | Louvain Universite Catholique | Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries |
| US5302386A (en) | 1986-04-16 | 1994-04-12 | Brigham And Women's Hospital, Inc. | Bacterial antigens, antibodies, vaccines and methods of manufacture |
| US5472696A (en) * | 1988-02-26 | 1995-12-05 | Univ. Of Florida Research Foundation, Inc. | Antigen of group B streptococci |
| US5648241A (en) | 1989-09-15 | 1997-07-15 | The General Hospital Corporation | Conjugate vaccine against group B streptococcus |
| JP4163251B2 (ja) * | 1992-09-24 | 2008-10-08 | ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | グループｂストレプトコッカス・タイプ▲ｉｉ▼およびタイプ▲ｖ▼多糖−蛋白質接合ワクチン |
| ZA937034B (en) | 1992-09-24 | 1995-06-23 | Brigham & Womens Hospital | Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines |
| US6355255B1 (en) | 1998-12-07 | 2002-03-12 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
| EP1810978B1 (en) | 2000-08-08 | 2013-02-13 | St. Jude Children's Research Hospital | Group B streptococcus polypeptides nucleic acids and therapeutic composition and vaccines thereof |
| AU2003257003A1 (en) | 2002-07-30 | 2004-02-16 | Baxter Healthcare S.A. | Chimeric multivalent polysaccharide conjugate vaccines |
-
2005
- 2005-11-01 AU AU2005302269A patent/AU2005302269B2/en not_active Ceased
- 2005-11-01 MX MX2007005202A patent/MX2007005202A/es unknown
- 2005-11-01 CA CA002586058A patent/CA2586058A1/en not_active Abandoned
- 2005-11-01 US US11/264,731 patent/US7858101B2/en not_active Expired - Fee Related
- 2005-11-01 CN CNA2005800440250A patent/CN101107010A/zh active Pending
- 2005-11-01 EP EP05851285A patent/EP1812057A4/en not_active Withdrawn
- 2005-11-01 JP JP2007539289A patent/JP2008518953A/ja active Pending
- 2005-11-01 WO PCT/US2005/039424 patent/WO2006050341A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008518953A5 (enExample) | ||
| DE68917126T2 (de) | T-zellen-epitope als träger für einen konjugierten impfstoff. | |
| US7972608B2 (en) | Carrier proteins for vaccines | |
| RU2014122163A (ru) | Комбинации, включающие сахарид пневмококка серотипа 14 | |
| JP4171068B2 (ja) | 修飾したメニンゴコッカスのポリサッカライドを結合したワクチン | |
| JP2006512402A5 (enExample) | ||
| JPH11507964A (ja) | ２，５−アンヒドロ−ｄ−マンノース末端構造を持つ、抗原性グループｂ連鎖球菌▲ｉｉ▼型および▲ｉｉｉ▼型多糖断片とその複合ワクチン | |
| JP2000507974A (ja) | 多糖―ペプチド複合体 | |
| HU228384B1 (en) | Vaccine compositions | |
| JP4024849B2 (ja) | インフルエンザウイルスのサブユニット複合体 | |
| RU2005119640A (ru) | Множественные варианты менингококкового белка nmbi1870 | |
| CA2504755A1 (en) | Carbohydrate-based synthetic vaccines for hiv | |
| CN103083652B (zh) | 一种以异型双功能试剂为连接桥的脑膜炎多糖结合疫苗及其制备方法 | |
| JP2012521404A5 (enExample) | ||
| JP4308174B2 (ja) | グループｂストレプトコッカス・タイプｉｉおよびタイプｖ多糖−蛋白質接合ワクチン | |
| CN101132810A (zh) | 含有肽聚糖的糖缀合物疫苗 | |
| JP2011504487A5 (enExample) | ||
| KR19990007777A (ko) | 면역성 및 면역자극성 올리고당 조성물 및 이를 제조하고 이용하는 방법 | |
| CN106659799A (zh) | 用于制备针对因肠致病性细菌引起的感染的广谱疫苗的包含表达内置的多个表位的分子构建体的基本单元的糖缀合物疫苗 | |
| WO2018096013A1 (en) | nOMV-ANTIGEN CONJUGATES AND USE THEREOF | |
| JP2012524099A5 (enExample) | ||
| JP2011504535A5 (enExample) | ||
| DE69713089T2 (de) | Verfahren zur herstellung von immunoaktiven mittel und impfstoffe | |
| Kaijser et al. | Protection against acute, ascending pyelonephritis caused by Escherichia coli in rats, using isolated capsular antigen conjugated to bovine serum albumin | |
| CN104096226B (zh) | 一种增强4价流行性脑膜炎球菌多糖蛋白结合物免疫原性的方法 |